Cure My Disease

Don't miss your cure!

 Log in / Sign up

A quick finger-prick test could spot hidden diabetes in rural villages

NCT ID NCT07718867

Diagnosis Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This trial tests whether a finger-prick HbA1c test can detect type 2 diabetes better than the standard random blood glucose test in at-risk adults living in rural Dali, China. Researchers will compare detection rates and costs among 720 permanent rural residents with no known diabetes but at high risk. The goal is to find a practical, affordable screening method for communities with limited access to laboratory testing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
point-of-care capillary HbA1c test (finger-prick) and fingerstick random blood glucose test
What this could lead to
If the finger-prick HbA1c test proves more effective and cost-effective, it could become a new standard for diabetes screening in rural areas with limited access to labs.
What could go wrong
This is a screening comparison, not a treatment trial. The HbA1c test may not be more accurate or cost-effective than the current method, and results may not apply outside rural China.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 720 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or above; * Permanent residents of Dali City who have lived locally for at least six consecutive months; * Registered as rural residents; * No known history of diabetes; * Meet at least one of the high-risk criteria for T2DM specified in the Chinese Guidelines for the Prevention and Treatment of Diabetes issued by the Chinese Diabetes Society; * Able to understand the study information and provide written informed consent. Exclusion Criteria: * Known history of T2DM or currently receiving glucose-lowering treatment; * HbA1c testing with a clear result within the past three months, or completion of standardised diabetes screening within the past six months; * Pregnant or breastfeeding at the time of recruitment; * Active thyroid disease or other active endocrine disorders at recruitment, such as Cushing's syndrome or acromegaly; * Known haemoglobinopathy, severe anaemia, recent acute blood loss, or history of blood transfusion or blood donation within the past three months; * Currently receiving treatment that may substantially affect interpretation of HbA1c, such as erythropoietin therapy or recent high-dose iron therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glucose intolerance prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre diabetes Type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First People's Hospital of Dali

    Dali, Yunnan, 671000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.